Highlights from the ACCC Working Summit: Biomarker Testing – Solutions for EHR Integration
Listen now
Description
Health technology performance and integration of electronic health record (EHR) systems—the creation of interfaces between EHRs and reference labs performing biomarker testing— have become critical factors in conducting efficient and equitable biomarker testing at cancer programs nationwide. At ACCC’s 40th Annual National Oncology Conference, an exclusive EHR Working Summit was held to understand barriers to integrating biomarker testing into EHR systems and explore effective practices/workaround solutions to facilitate timely and comprehensive biomarker testing. In this episode, CANCER BUZZ speaks with Karen Huelsman, MS, LGC, precision oncology lead and genetic counselor at TriHealth Cancer and Blood Institute, who also serves on ACCC’s EHR Integration program Advisory Committee, about key takeaways and insights from the Working Summit.  “Some of the key barriers include limited staffing on information systems and technical teams—that’s the number one ingredient—[also] funding is an important element, having enough FTEs [full-time employees] to create a team, having knowledgeable data engineers and project coordinators…and trying to include some level of clinical input for any new integration implementation team is really important, and those are not always available…” – Karen Huelsman, MS, LGC Guest:         Karen Huelsman, MS, LGC Precision Oncology Lead, Genetic Counselor TriHealth Cancer and Blood Institute Cincinnati, Ohio This episode was developed in connection with the ACCC education program EHR Integration: Effective Practices to Facilitate Timely and Comprehensive Biomarker Testing. This educational program is made possible with support by AstraZeneca and Genentech. Additional Reading/Sources EHR Integration: Effective Practices to Facilitate Timely and Comprehensive Biomarker Testing EHR Integration Landscape Analysis
More Episodes
The range of frontline therapy options for mantle cell lymphoma can influence subsequent treatment choices for patients with relapsed or refractory disease. Providers must determine initial treatment based on individual patient characteristics, while also factoring in future treatment options. In...
Published 09/19/24
Advancements in treatment combined with a multimodal approach are improving outcomes for patients with head and neck cancer. However, the unique challenges of a head and neck cancer diagnosis and its treatment side effects—such as speech and communication difficulties as well as negative effects...
Published 09/12/24
Published 09/12/24